Avidity Biosciences Files 8-K
| Field | Detail |
|---|---|
| Company | Avidity Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40.00, $37.70, $564.0 m, $648.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: AVDX
TL;DR
AVDX filed an 8-K on 9/12 for 9/11 events. Check for updates.
AI Summary
Avidity Biosciences, Inc. filed an 8-K on September 12, 2025, reporting other events and financial statements/exhibits. The filing pertains to events occurring on September 11, 2025. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing indicates that Avidity Biosciences has made a regulatory submission, which could contain important updates regarding their business operations, financial status, or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events but does not inherently introduce new risks without specific details within the filing.
Key Players & Entities
- Avidity Biosciences, Inc. (company) — Registrant
- September 11, 2025 (date) — Earliest event reported
- September 12, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as the items being reported, with the earliest event date being September 11, 2025.
When was this 8-K report filed with the SEC?
The report was filed on September 12, 2025.
What is Avidity Biosciences, Inc.'s principal executive office address?
The principal executive offices are located at 3020 Callan Road, San Diego, California 92121.
In which state is Avidity Biosciences, Inc. incorporated?
Avidity Biosciences, Inc. is incorporated in Delaware.
What is the company's telephone number?
The company's telephone number is (858) 401-7900.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 11.6 · Accepted 2025-09-12 17:23:24
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RNA The Nasdaq Global Mar
- $40.00 — price to the public in this offering is $40.00 per share. The Underwriters have agreed
- $37.70 — he Underwriting Agreement at a price of $37.70 per share. In addition, under the terms
- $564.0 m — fering are expected to be approximately $564.0 million, or approximately $648.8 million
- $648.8 million — mately $564.0 million, or approximately $648.8 million if the Option is exercised in full, aft
Filing Documents
- d25770d8k.htm (8-K) — 31KB
- d25770dex11.htm (EX-1.1) — 227KB
- d25770dex51.htm (EX-5.1) — 13KB
- d25770dex991.htm (EX-99.1) — 9KB
- d25770dex992.htm (EX-99.2) — 10KB
- g25770g0912121223204.jpg (GRAPHIC) — 2KB
- g25770g0912121628416.jpg (GRAPHIC) — 5KB
- g25770g0912131107740.jpg (GRAPHIC) — 2KB
- 0001193125-25-202371.txt ( ) — 487KB
- rna-20250911.xsd (EX-101.SCH) — 3KB
- rna-20250911_lab.xml (EX-101.LAB) — 17KB
- rna-20250911_pre.xml (EX-101.PRE) — 11KB
- d25770d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated September 11, 2025, by and among Avidity Biosciences, Inc. and Leerink Partners LLC, J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein 5.1 Opinion of Latham & Watkins LLP 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1) 99.1 Press Release dated September 10, 2025 99.2 Press Release dated September 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVIDITY BIOSCIENCES, INC. Date: September 12, 2025 By: /s/ Michael F. MacLean Michael F. MacLean Chief Financial Officer